Week 58 (Dose increase to 0.5 mg): When the dose is increased to 0.5 mg (the first therapeutic dose), patients may experience a recurrence or intensification of gastrointestinal side effects , though typically less severe than the initial response
cohort, worse BCVA at 90 days was associated with worse presenting BCVA, longer time until presentation, larger area of stromal infiltrate and, perhaps curiously, an absence of contact lens use in the history
The comparison between GLP-1RA and SGLT-2 inhibitors showed no difference in their risks of MACE, nonfatal MI, nonfatal stroke, CV and total death
Most research can be boring, and this whole notion of working with venoms sounded cool and intriguing, he says
A.SalazarA.Del PozoE